Last $21.35 USD
Change Today -1.63 / -7.09%
Volume 35.8K
ARDX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

ardelyx inc (ARDX) Snapshot

Open
$23.08
Previous Close
$22.98
Day High
$24.49
Day Low
$21.06
52 Week High
10/6/14 - $25.23
52 Week Low
08/7/14 - $11.37
Market Cap
395.7M
Average Volume 10 Days
60.9K
EPS TTM
--
Shares Outstanding
18.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARDELYX INC (ARDX)

Related News

No related news articles were found.

ardelyx inc (ARDX) Related Businessweek News

No Related Businessweek News Found

ardelyx inc (ARDX) Details

Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 and is headquartered in Fremont, California.

36 Employees
Last Reported Date: 08/8/14
Founded in 2007

ardelyx inc (ARDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $416.3K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $310.0K
Vice President of Drug Development
Total Annual Compensation: $277.5K
Compensation as of Fiscal Year 2013.

ardelyx inc (ARDX) Key Developments

Ardelyx, Inc. - Special Call

To discuss the Phase 2b IBS-C results

Ardelyx Reports Positive Results from its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients

Ardelyx, Inc. announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). Results from this study demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. At the 50 mg dose, the study met its primary efficacy endpoint of an increase in the complete spontaneous bowel movement (CSBM) responder rate. Most secondary endpoints, including abdominal pain and other abdominal and IBS-C symptoms, demonstrated clinically meaningful improvements. Tenapanor was well-tolerated, and the safety results were consistent with those observed in previous tenapanor trials. Tenapanor, a minimally-absorbed inhibitor of the intestinal sodium transporter NHE3, has demonstrated the ability to reduce the absorption of dietary sodium and phosphate. Ardelyx licensed tenapanor to AstraZeneca in October 2012. In addition to IBS-C, Ardelyx and AstraZeneca are evaluating tenapanor for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) in an ongoing Phase 2b study, and in an ongoing Phase 2a study, tenapanor is being evaluated for its effect on markers of kidney disease and fluid status in patients with chronic kidney disease (CKD). Phase 2b randomized, double-blind, placebo-controlled clinical trial in 150 ESRD patients to evaluate the effects of tenapanor on serum phosphorus. Enrollment is ongoing and the results of this clinical trial are expected in the first half of 2015. Stage 3 CKD patients with type 2 diabetes mellitus, the presence of the protein albumin in the urine, or albuminuria, and high blood pressure: Phase 2a randomized, double-blind, placebo-controlled clinical trial in 140 patients to evaluate the effects of tenapanor on kidney function and fluid overload. Enrollment is ongoing and the results of this clinical trial are expected in the second half of 2015.

Ardelyx, Inc.(NasdaqGM:ARDX) added to Russell 2000 Index

Ardelyx, Inc. will be added to the Russell 2000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARDX:US $21.35 USD -1.63

ARDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARDX.
View Industry Companies
 

Industry Analysis

ARDX

Industry Average

Valuation ARDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARDELYX INC, please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.